Advertisement

Prevention of Tardive Dyskinesia

  • Edmond H. Pi
  • George M. Simpson

Abstract

Neuroleptics produce many unwanted effects including extrapyramidal side effects. The latter usually occur early in treatment and are seen frequently in psychiatric practice. Recently, much attention has been given to the late-onset condition, tardive dyskinesia (TD). Despite the fact that this syndrome was described in the literature soon after the introduction of neuroleptics in the early 1950s (Schonecker, 1957: Sigwald et al., 1959), there is still wide disagreement among investigators regarding its prevalence (estimates have ranged from 0.5% to 56%). This reflects the need for a precise definition of TD (Simpson et al., 1982) and has hampered clinicians’ efforts to make an early diagnosis of TD. The availability of standardized, objectively defined rating scales (NIMH, 1975; Simpson et al.,1979) and other diagnostic devices represents a significant advance in clarifying these problems (Schooler and Kane, 1982). These developments provide clinicians with a useful tool to objectively document the evolution and severity of TD. This represents the first step toward the goal of preventing the debilitating and sometimes irreversible effects of this disorder.

Keywords

Tardive Dyskinesia Fusaric Acid Extrapyramidal Side Effect Drug Holiday Fluphenazine Decanoate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexopoulos, G. S., 1979, Lack of complaints in schizophrenics with tardive dyskinesia, J. Nerv. Ment. Dis. 167: 125–127.PubMedCrossRefGoogle Scholar
  2. Alpert, M., and Friedhoff, A. J., 1980, Clinical application of receptor modification treatment, in: Tardive Dyskinesia—Research and Treatment ( W. E., Fann, R. C. Smith, J. M. Davis, and E. F. Domino, eds.), pp. 471–473, SP Medical and Scientific Books, New York.CrossRefGoogle Scholar
  3. Baldessarini, R. J., and Tarsy, D., 1978, Tardive dyskinesia, in: Psychopharmacology: A Generation of Progress ( M. A. Lipton, A. DiMascio, and K. F. Killam, eds.), pp. 993–1004, Raven Press, New York.Google Scholar
  4. Bjorndal, N., Casey, D. E., Gerlach, J., Hansen, H., Korsgaard, S., and Rasmussen, J. 1980, The effects of levodopa in tardive dyskinesia, in: Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies ( E. Usdin, ed.), pp. 321–324, Elsevier North Holland, Amsterdam.Google Scholar
  5. Casey, D. E., 1985, Tardive dyskinesia: Reversible and irreversible, in: Dyskinesia Research and Treatment (D. E. Casey et al.,eds.), pp. 88–97, Springer-Verlag, New York.Google Scholar
  6. Casey, D. E., and Denney, D., 1977, Pharmacological characterization of tardive dyskinesia, Psy-chopharmacology 54: 1–8.Google Scholar
  7. Chouinard, G., deMoutigny, C., and Annable, L., 1979, Tardive dyskinesia and antiparkinsonian medication, Am. J. Psychiatry 136: 228–229.PubMedGoogle Scholar
  8. Crane, G. E., 1968, Tardive dyskinesia in patients treated with major neuroleptics: A review of the literature, Am. J. Psychiatry 124 (Suppl.): 40–48.Google Scholar
  9. Crane, G. E., 1972, Psuedoparkinsonism and tardive dyskinesia, Arch. Neurol. 27: 426–430.PubMedCrossRefGoogle Scholar
  10. Crane, G. E., 1973, Persistent dyskinesia, Br. J. Psychiatry 122: 395–405.PubMedCrossRefGoogle Scholar
  11. Crane, G. E., 1976, Risks of long-term therapy with neuroleptic drugs, in: Antipsychotic Drugs: Pharmacodynamics and Pharmacokinetics ( G. Sedvall, B. Uvnas, and G. Y. Zotterman, Eds.), pp. 441–419, Pergamon Press, New York.Google Scholar
  12. Crane, G. E., 1977, The prevention of tardive dyskinesia, Am. J. Psychiatry 134: 756–758.PubMedGoogle Scholar
  13. Curry, S. H., Davis, J. M., Janowsky, D. S., et al.,1970, Factors affecting chlorpromazine plasma levels in psychiatric patients, Arch. Gen. Psychiatry 22:209–215.Google Scholar
  14. Davis, K. L., Berger, P. A., and Hollister, L. E., 1976, Tardive dyskinesia and depressive illness, Psychopharmacol. Commun. 2: 125–130.PubMedGoogle Scholar
  15. Defraites, E. G., Davis, K. L., and Berger, P. A., 1977, Coexisting tardive dyskinesia and parkinsonism: A case report, Biol. Psych. 12: 267–272.Google Scholar
  16. Donatelli, A., Geisen, L., and Feuer, E., 1983. Case report of adverse effect of reserpine on tardive dyskinesia, Am. J. Psychiatry 140: 239–240.PubMedGoogle Scholar
  17. Fairbairn, A. F., Rowell, F. J., Hui, S. H., Hassanyeh, F., Robinson, A. J., and Decdeston, D., 1983. Serum concentration of depot neuroleptics in tardive dyskinesia, Br. J. Psychiatry 142: 579–583.PubMedCrossRefGoogle Scholar
  18. Fallon, I. R. H., Boyd, J. L., McGill, C. W., et al.,1985, Family management in the prevention of morbidity of schizophrenia, Arch. Gen. Psychiatry 42:887–896.Google Scholar
  19. Gardos, G., and Cole, J. O., 1983. Tardive dyskinesia and anticholinergic drugs, Am. J. Psychiatry 140: 200–202.PubMedGoogle Scholar
  20. Gerlach, J., 1977, The relationship between parkinsonism and tardive dyskinesia, Am. J. Psychiatry 134: 781–783.PubMedGoogle Scholar
  21. Gerlach, J., 1979, Tardive dyskinesia, Dan. Med. Bull. 26: 209–245.PubMedGoogle Scholar
  22. Gerlach, J., Rye, T., and Kristjansen, P., 1978, Effect of Baclofen on tardive dyskinesia, Psychopharmacology 56: 145–151.PubMedCrossRefGoogle Scholar
  23. Glazer, W. M., Moore, D. C., Schooler, N. R., Brenner, L. M., and Morgenstern, H., 1984, Tardive dyskinesia, a discontinuation study. Arch. Gen. Psychiatry 41: 623–629.CrossRefGoogle Scholar
  24. Gordon, J. H., Borison, R. L., and Diamond, B. T., 1980, Modulation of dopamine receptor sensitivity by estrogen, Biol. Psychiatry 15: 389–396.PubMedGoogle Scholar
  25. Granacher, R. P., 1981, Differential diagnoses of tardive dyskinesia: An overview, Am. J. Psychiatry 138: 1288–1297.PubMedGoogle Scholar
  26. Growdon, J., 1979, Choline and lecithin administration to patients with tardive dyskinesia, Can. J. Neurol. Sci. 6: 80.Google Scholar
  27. Harma, B. J., Nasrallah, H. A., Clancy, J., and Finn, R., 1983, Psychiatric diagnosis and risk for tardive dyskinesia, Arch. Gen. Psychiatry 40: 346–347.Google Scholar
  28. Heinrich, K., Wegener, I., and Bender, H. J., 1968, Spate extrapyramidal hyperkinesen bei neu-roleptischer Langzeit-Therapie, Pharmakopsychiatry Neuropsychopharmakol. 1: 169–195.Google Scholar
  29. Hunter, R., Earl, C. J., and Thornicroft, S., 1964, An apparently irreversible syndrome of abnormal movements following phenothiazine medication, Proc. Roy. Soc. Med. 57: 758–762.PubMedGoogle Scholar
  30. Jeste, D. V., and Wyatt, R. J., 1982, Therapeutic strategies against tardive dyskinesia. Two decades of experience, Arch. Gen. Psychiatry 39: 803–816.PubMedCrossRefGoogle Scholar
  31. Jeste, D. V., and Wyatt, R. J., 1983, Clozapine and tardive dyskinesia, Arch. Gen. Psychiatry 40: 347–348.CrossRefGoogle Scholar
  32. Jeste, D. V., Rosenblatt, J. E., Wagner, R. L., and Wyatt, R. J., 1979, High serum neuroleptic levels in tardive dyskinesia? N. Engl. J. Med. 301: 1184.PubMedGoogle Scholar
  33. Johnson, G. F. S., Hunt, G. E., and Rey, J. M., 1982, Incidence and severity of tardive dyskinesia increase with age, Arch. Gen. Psychiatry 39: 486.PubMedCrossRefGoogle Scholar
  34. Kane, J. M., and Smith, J. M., 1982, Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979, Arch. Gen. Psychiatry 39: 473–481.PubMedCrossRefGoogle Scholar
  35. Kane, J. M., Woerner, M., Weinhold, P., Wegner, J., and Kinon, B., 1982, A prospective study of tardive dyskinesia development: Preliminary results, J. Clin. Pharmacol. 2: 345–349.Google Scholar
  36. Kazamatsuri, H., Chien, C. P., and Cole, J. O., 1973, Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine, Am. J. Psychiatry 130: 479–483.Google Scholar
  37. Kiloh, L. G., Smith, J. S., and Williams, S. E., 1973, Antiparkinson drugs as causal agents in tardive dyskinesia, Med. J. Aust. 2: 591–593.PubMedGoogle Scholar
  38. Klawans, H. L., Tanner, C. M., and Barr, A., 1984, The reversibility of “permanent” tardive dyskinesia, Clin. Neuropharmacol. 7: 153–159.PubMedCrossRefGoogle Scholar
  39. Kraepelin, E., 1919, Dementia Praecox and Paraphrenia (R. M. Barclay, Translator), Livingstone, Edinburgh.Google Scholar
  40. Laska, E., Varga, E., Wanderung, J., Simpson, G., Logemann, G. W., and Shah, B. K., 1973, Patterns of psychotropic drug use for schizophrenia, Dis. Nerv. Syst. 34: 294–305.PubMedGoogle Scholar
  41. McClelland, H. A., Blessed, G., Bhata, S., Ali, N., and Clarke, P., 1974, Abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients, Br. J. Psychiatry 124: 151–159.PubMedCrossRefGoogle Scholar
  42. McClelland, H. A., Farquharson, R. G., Leyburn, P., Furness, J. A., and Schiff, A. A., 1976, Very high dose fluphenazine decanoate: A controlled trial in chronic schizophrenia, Arch. Gen. Psychiatry 33: 1435–1439.PubMedCrossRefGoogle Scholar
  43. Mukherjee, S., Rosen, A. M., Cardenas, C., Varia, V., and Olarte, S., 1982, Tardive dyskinesia in psychiatric outpatients: A study of prevalence and association with demographic, clinical and drug history variables, Arch. Gen. Psychiatry 36: 466–469.CrossRefGoogle Scholar
  44. National Institute of Mental Health, Psychopharmacology Research Branch, 1975, Development of a dyskinetic movement scale, Early Clinical Drug Evaluation Unit 4: 3–6.Google Scholar
  45. Ogita, K., Yagi, G., and Itoh, H., 1975, Comparative analysis of persistent dyskinesia of longterm usage with neuroleptics in France and in Japan, Folia Psychiatr. Neurol. Jpn. 29: 315–320.PubMedGoogle Scholar
  46. Owens, D. G. C., Johnstone, E. C., and Frith, C. D., 1982, Spontaneous involuntary disorders of movement, their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics, Arch. Gen. Psychiatry 39: 452–461.PubMedCrossRefGoogle Scholar
  47. Perris, C., Dimitrijevic, P., Jacobsson, L., Paulsson, P., Rapp, W., and Froberg, H., 1979, Tardive dyskinesia in psychiatric patients treated with neuroleptics, Br. J. Psychiatry 135: 509–514.PubMedCrossRefGoogle Scholar
  48. Pert, A., Rosenblatt, J. E., Sivit, C., Pert, C. B., and Bunney, W. E., Jr., 1978, Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity, Science 201: 171–173.PubMedCrossRefGoogle Scholar
  49. Pi, E. H., and Simpson, G. M., 1981a, The treatment of refractory schizophrenia: Pharmacotherapy and clinical implications of blood level measurement of neuroleptics, Int. J. Pharmacopsychiatry 16: 154–161.Google Scholar
  50. Pi, E. H., and Simpson, G. M., 1981b, Tardive dyskinesia and abnormal tongue movements, Br. J. Psychiatry 139: 526–528.PubMedCrossRefGoogle Scholar
  51. Pi, E. H., Miller, A., Rosenberg, M. R., Schultz, C., and Simpson, G. M., 1983, Therapeutic effects of psychiatric hospitalization, J. Psychiatr. Eval. Treatment 5: 135–142.Google Scholar
  52. Quitkin, F., Rifkin, A., Gochfeld, L., and Klein, D. F., 1977, Tardive dyskinesia: Are first signs reversible? Am. J. Psychiatry 134: 84–87.PubMedGoogle Scholar
  53. Rosen, A. M., Mukherjee, S. Olarte, S., Varia, V., and Cardenas, C., 1982, Perception of tardive dyskinesia in outpatients receiving maintenance neuroleptics, Am. J. Psychiatry 139: 372–373.Google Scholar
  54. Rosenbaum, A. H., Niven, R. G., Hanson, N. P., and Swanson, D. W., 1977, Tardive dyskinesia: Relationship with a primary affective disorder, Dis. Nerv. Syst. 38: 423–427.PubMedGoogle Scholar
  55. Rubovits, R., and Klawans, H. L., 1972, Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesia, Arch. Gen. Psychiatry 27: 502–507.PubMedCrossRefGoogle Scholar
  56. Schonecker, M., 1957, Ein eigentumlichen syndrom im oralem bereich bei Megaphen applikation, Nervenarzt 28: 35.Google Scholar
  57. Schooler, N. R., and Kane, J. M., 1982, Research diagnoses for tardive dyskinesia, Arch. Gen. Psychiatry 39: 486–487.Google Scholar
  58. Schrodt, G. R., Wright, J. H., Simpson, R., Moore, D. P., and Chase, S., 1982, Treatment of tardive dyskinesia with propranolol, J. Clin. Psychiatry 42: 328–331.Google Scholar
  59. Senn, H. J., Jungi, W. F., Kunz, H., and Poldinger, W., 1977, Clozapine and agranulocytosis, Lancet 1: 547.PubMedCrossRefGoogle Scholar
  60. Sigwald, J., Bouttier, D., Raymond, C., and Piot, C., 1959, Quatre cas de dyskinesie famio-buciolinguo-masticatrice a evolution prolongee secondaire a un traitment par les neuroleptiques, Rev. Neurol. 100: 751–755.PubMedGoogle Scholar
  61. Simpson, G. M., 1975, CNS effects of neuroleptic agents, Psychiatr. Ann. 5: 53–60.Google Scholar
  62. Simpson, G. M., and Kline, N. S., 1976, Tardive dyskinesia: Manifestation, incidence, etiology and treatment, in: The Basal Ganglion ( M. D. Yahr, ed.), pp. 427–432, Raven Press, New York.Google Scholar
  63. Simpson, G. M., and Lee, H., 1978, A ten-year Review of antipsychotics, in: Psychopharmacology, A Generation of Progress ( M. A. Lipton, A. SiMascio, and K. F., Killam, eds.), pp. 1131–1137, Raven Press, New York.Google Scholar
  64. Simpson, G. M., and Pi, E. H., 1981, Pharmacokinetics of antipsychotic agents, in: Recent Ad-vances in Neuropsychopharmacology, Vol. 31 (B. Angrist, ed.,), pp. 365–372, Pergamon Press, Oxford, New York.Google Scholar
  65. Simpson, G. M., Krakov, L., Mattke, D., and St. Phard, G., 1970, A controlled comparison of the treatment of schizophrenic patients when treated according to the neuroleptic threshold or by clinical judgement, Acta Psychiatr. Scand. 212 (Suppl.): 38–43.PubMedGoogle Scholar
  66. Simpson, G. M., Voitashevsky, A., Young, M. A., and Lee, J. H., 1977, Deanol in the treatment of tardive dyskinesia, Psychopharmacology 52: 257–261.PubMedCrossRefGoogle Scholar
  67. Simpson, G. M., Varga, E., Lee, J. H., and Zoubok, B., 1978, Tardive dyskinesia and psychotropic drug history, Psychopharmacology 58: 117–124.PubMedCrossRefGoogle Scholar
  68. Simpson, G. M., Lee, J. H., Zoubok, B., and Gardos, G., 1979, A rating scale for tardive dyskinesia, Psychopharmacology 64: 171–179.PubMedCrossRefGoogle Scholar
  69. Simpson, G. M., Pi, E. H., and Sramek, J. J., 1981, Adverse effects of antipsychotic agents, Drugs 21: 138–151.PubMedCrossRefGoogle Scholar
  70. Simpson, G. M., Pi, E. H., and Sramek, J. J., 1982, Management of tardive dyskinesia: Current update, Drugs 23: 381–393.PubMedCrossRefGoogle Scholar
  71. Simpson, G. M., Pi, E. H., and Sramek, J. J., 1983, The current status of tardive dyskinesia, J. Psychiatr. Eval. Treatment 4: 127–133.Google Scholar
  72. Singer, J. M., 1983, Clozapine and tardive dyskinesia, Arch. Gen. Psychiatry 40: 347–348.PubMedCrossRefGoogle Scholar
  73. Smith, R. C., Tamminga, C. A., Haraszti, J., Pandey, G. N., and Davis, J. M., 1977, Effects of dopamine agonists in tardive dyskinesia, Am. J. Psychiatry 134: 753–768.Google Scholar
  74. Smith, R. C., Strizich, M., and Klass, D., 1978, Drug history and tardive dyskinesia, Am. J. Psychiatry. 135: 1402–1403.PubMedGoogle Scholar
  75. Tarsy, D., and Baldessarini, R. J., 1977, The pathophysiologic basis of tardive dyskinesia, Biol. Psychiatry 12: 431–450.PubMedGoogle Scholar
  76. Turek, I. S., 1975, Drug-induced dyskinesia: Reality or myth? Dis. Nerv. Syst. 36: 397–399.PubMedGoogle Scholar
  77. Varga, E., Sugerman, A. A., Varga, V., Zomorodi, A., Zomorodi, W., and Menken, M., 1982, Prevalence of spontaneous oral dyskinesia in the elderly, Am. J. Psychiatry 139: 329–331.PubMedGoogle Scholar
  78. Wegner, J. T., and Kane, J. M., 1982, Follow-up study on the reversibility of tardive dyskinesia, Am. J. Psychiatry 39: 368–369.Google Scholar
  79. Yassa, R., and Nair, V., 1984, Incidence of tardive dyskinesia in an outpatient population, Psychosomatics 75: 479–481.CrossRefGoogle Scholar
  80. Yassa, R., Nair, V., and Schwartz, G., 1984. Tardive dyskinesia and the primary psychiatric diagnosis, Psychosomatics 25: 135–138.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1986

Authors and Affiliations

  • Edmond H. Pi
    • 1
  • George M. Simpson
    • 2
  1. 1.Department of PsychiatryUniversity of Southern California School of MedicineLos AngelesUSA
  2. 2.Department of PsychiatryThe Medical College of PennsylvaniaPhiladelphiaUSA

Personalised recommendations